10-Q quarterly report · filed Nov 3, 2026

ARDELYX, INC. (ARDX) Q3 2026 10-Q Quarterly Report

Short answer

ARDELYX, INC. (ARDX) filed its Q3 2026 10-Q quarterly report on Nov 3, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $128M (up 15.7% year over year) with net income of −$737,000.

Q3 2026 key financials · XBRL

Revenue
$128M
+15.7% YoY · +5.6% QoQ
Net income
−$737,000
+23.9% YoY · +95.6% QoQ
Operating margin
3.2%
EPS (diluted)
$0.00
+100.0% QoQ

Source: XBRL data from the ARDELYX, INC. (ARDX) Q3 2026 10-Q on SEC EDGAR. USD.

ARDELYX, INC. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue $127.655M vs $110.329M, up $17.326M YoY
  • GTN adjustment rate 31.7% vs 30.6%; unfavorable channel mix and higher rebate charges
  • Best performer IBSRELA sales $96.286M vs $78.158M; XPHOZAH sales $29.169M vs $27.357M
  • Liquid funds $285.338M vs $264.689M; Term F Loan added $50.0M
  • Operating cash use $36.465M, down from $63.434M; outlook funds operations at least one year

Risk Factors

  • New regulatory risk: March 27, 2026 CMS guidance expects ESRD facilities to furnish XPHOZAH under bundled payment
  • Most material update: June 26, 2026 appellate dismissal upheld XPHOZAH’s ESRD PPS challenge
  • Operational risk: Three manufacturing stages rely on single-source CMOs with no qualified alternatives
  • Financial risk: $200.0 million outstanding principal under SLR term loans as of September 30, 2026
  • Competitive risk: At least four phosphate binders remain in development, including two Phase 3 programs

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other ARDELYX, INC. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.